Background {#Sec1}
==========

*Mycoplasma* sp. 1220 was first described as a new *Mycoplasma* species by Stipkovits et al. in 1986 \[[@CR1]\]. This *Mycoplasma* species causes cloaca and phallus inflammation and testicular atrophy in the ganders \[[@CR1], [@CR2]\]. In the infected geese salpingitis and vaginitis are the main symptoms \[[@CR1], [@CR3]\]. The egg production activates the pathogen and the flared up mycoplasmosis could induce lethal pathological changes in the embryos \[[@CR1], [@CR4]\]. Airsacculitis and peritonitis are also common, and general symptoms such as changes in thirst, decreased food consumption, body weight losses, weakness, nasal discharge, impaired breathing, conjunctivitis, diarrhoea and nervous signs were also described in the affected waterfowl flocks \[[@CR2], [@CR5]--[@CR8]\]. *Mycoplasma* infection of the birds can aggravate diseases caused by other agents and could lead to serious economic losses \[[@CR3], [@CR6]\]. Since there is no commercially available vaccine against *M*. sp. 1220, adequate housing and appropriate antibiotic treatment are promoted in the control of the diseases caused by this agent. Prophylactic medication could prevent economic losses if appropriate antibiotics are administered in the early weeks of life and in expected stress periods. Medication of the layers is essential to reduce the vertical transmission of *M.* sp. 1220 \[[@CR2]\].

*Mycoplasmas* are resistant to β-lactam antimicrobials because of the lack of cell-wall and the bacteria are also resistant to membrane synthesis inhibitors \[[@CR2], [@CR9]\]. Antibiotics such as quinolones, tetracyclines, macrolides and pleuromutilins which induce DNA fragmentation or inhibition at the level of protein synthesis are the drugs of choice for the therapy of mycoplasmosis. Among the macrolides, erythromycin showed high effectiveness against *Mycoplasma* strains which could ferment glucose (e.g. *M.* sp. 1220), while arginine-hydrolysing strains proved to be less susceptible to this compound \[[@CR2], [@CR10]\]. *Mycoplasma* infected waterfowl and poultry flocks are usually treated with macrolides, pleuromutilins or with the combination of lincomycin and spectinomycin \[[@CR3], [@CR11]--[@CR18]\].

The aim of this study was to determine the susceptibility of 38 Hungarian *M*. sp. 1220 isolates to thirteen antibiotics and a drug combination using the microbroth dilution method.

Methods {#Sec2}
=======

A total of 38 *M.* sp. 1220 strains isolated from geese and a duck originating from different parts of Hungary were tested in the study (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). The samples were collected during routine diagnostic examinations or necropsies between 2011 and 2015, thus ethical approval was not required for the study. Phallus lymph, cloaca swabs, tracheal swabs, follicules and lung samples were washed in 2 ml of *Mycoplasma* broth medium (pH 7.8) (ThermoFisher Scientific Inc./Oxoid Inc./, Waltham, MA) supplemented with 0.5 % (w/v) sodium pyruvate, 0.5 % (w/v) glucose and 0.005 % (w/v) phenol red and incubated at 37 °C in a 5 % CO~2~ atmosphere. The cultures were inoculated onto solid *Mycoplasma* media (Thermo Fisher Scientific Inc./Oxoid Inc./) after colour change of the broth, and were incubated at 37 °C and 5 % CO~2~ until visible colonies appeared (1--2 days). Purification of mixed cultures was performed by one-time filter cloning, minimizing the in vitro mutations of the isolates. The QIAamp DNA Mini Kit (Qiagen Inc., Hilden, Germany) was used for DNA extraction according to the manufacturers' instructions for Gram-negative bacteria. The purity of the cultures was confirmed by a universal *Mycoplasma* PCR system targeting the 16S/23S rRNA intergenic spacer region in *Mycoplasmatales* followed by sequencing on an ABI Prism 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA), sequence analysis and BLAST search \[[@CR19]\]. The number of colour changing units (CCU) was calculated by microbroth dilution method, from the lowest dilution showing colour change after one week of incubation \[[@CR9]\].Table 1Background data and MIC values of the isolated *Mycoplasma* sp. 1220 strainsMIC values (μg/ml)FluoroquinolonesAminoglycosideLincosamideTetracyclinesMacrolidesPleuromutilinesPhenicolSample IDSample sourcePlaceAnimalDateEnrofloxacinNorfloxacinDifloxacinSpectinomycinLincomycinLincomycin-spectinomycin (1:2) combinationOxytetracyclineDoxycyclineTylosinTilmicosinTylvalosinTiamulinValnemulinFlorfenicolMYCAV 65Phallus lymphRémgoose20145\>101016443250.50.5≤0.251.250.0788MYCAV 34Phallus lymphSzentesgoose20115\>1010842642.514≤0.250.625≤0.0394MYCAV 35Phallus lymphRémgoose20125\>1010\>6444641014≤0.251.25≤0.0398MYCAV 36CloacaHajdúböszörménygoose20125\>10\>10644464\>1014≤0.251.25≤0.0398MYCAV 38CloacaKelebiagoose20122.5\>101082440.156≤0.25≤0.25≤0.250.625≤0.0394MYCAV 44CloacaNagykamarásgoose20125\>101084480.3128\>640.51.25≤0.0398MYCAV 47LungTázlárduck2012\>10\>10\>1016\>6416\>64516\>6412.50.3128MYCAV 49Phallus lymphTiszavasvárigoose20135\>101016446458\>640.50.625≤0.0398MYCAV 50Phallus lymphCeredgoose2013\>10\>10\>101644\>64522≤0.250.625≤0.0398MYCAV 51Phallus lymphDerekegyházgoose20135\>10103244\>64108\>640.50.625≤0.0398MYCAV 53Phallus lymphSzentesgoose20135\>10101644\>64108\>640.50.625≤0.0398MYCAV 54FolliculeHódmezővásárhelygoose20135\>1010844\>6458\>640.50.625≤0.0398MYCAV 55FolliculeKiskunmajsagoose201310\>101084480.312≤0.25≤0.25≤0.250.625≤0.0394MYCAV 56Phallus lymphSükösdgoose20131.25\>101.2584440.3128\>640.50.625≤0.0394MYCAV 59FolliculeRémgoose20135\>1010844322.50.5≤0.25≤0.251.250.0782MYCAV 61Phallus lymphTatárszentgyörgygoose20135\>1010162420.078≤0.25≤0.25≤0.250.312≤0.0394MYCAV 63TracheaSükösdgoose20131.25101.2582240.312464≤0.250.156≤0.0394MYCAV 66Phallus lymphTiszaföldvárgoose20145\>10101644\>64\>10≤0.25≤0.25≤0.250.625≤0.0394MYCAV 67Phallus lymphSzentesgoose20145\>10108\>6416\>645\>64\>64162.50.0784MYCAV 68Phallus lymphÉrpatakgoose20145\>10108\>6432\>6410\>64\>64165≤0.0398MYCAV 69Phallus lymphLudasgoose20145\>1010444\>6458\>6410.625≤0.0394MYCAV 70Phallus lymphCeredgoose2014\>10\>10\>101644\>64\>1016\>6410.625≤0.0398MYCAV 71Phallus lymphSükösdgoose20141.25\>101.2582480.6258\>640.50.625≤0.0394MYCAV 72Phallus lymphNagykamarásgoose20145\>101084440.3128\>640.50.625≤0.0394MYCAV 75Phallus lymphDömsödgoose20145\>10101644\>6410≤0.25≤0.25≤0.250.625≤0.0398MYCAV 76Phallus lymphTiszabábolnagoose20145\>101032846458\>640.51.25≤0.0398MYCAV 91Phallus lymphHajdúsámsongoose201110\>10\>10884642.5≤0.25≤0.25≤0.250.625≤0.0398MYCAV 93Phallus lymphBojtgoose20142.5\>101.2582480.312≤0.25≤0.25≤0.250.312≤0.0398MYCAV 94CloacaTiszabábolnagoose20122.5\>1051644\>64\>10≤0.25≤0.25≤0.250.625≤0.0398MYCAV 160Phallus lymphÉrpatakgoose2015\>10\>10\>101644\>6410\>64\>6420.625≤0.0398MYCAV 161Phallus lymphSzilaspogonygoose2015\>10\>10\>10844\>64\>1016\>640.50.625≤0.0398MYCAV 162Phallus lymphEncsencsgoose20152.5\>1010844\>64516\>640.50.625≤0.0394MYCAV 176Phallus lymphCeredgoose201510\>105844\>64564\>6440.625≤0.03916MYCAV 177Phallus lymphCeredgoose2015\>10\>1010844\>6410\>64\>6440.625≤0.03932MYCAV 178FolliculeCeredgoose20155\>1010824\>6454\>640.50.312≤0.0394MYCAV 179TracheaApátfalvagoose201510\>1010164440.312440.51.25≤0.0398MYCAV 180Phallus lymphKisbérgoose20155\>1010\>644440.31232\>6411.25≤0.0398MYCAV 202CloacaKelebiagoose20155\>1051644322.50.50.5≤0.251.25≤0.0398Fig. 1Map of Hungary showing the geographical origin of the *Mycoplasma* sp. 1220 isolates. Size of the circles indicates the number (*n*) of the strains. (The blank map was downloaded from an open source \[[@CR28]\])

The following antimicrobial agents were examined during the microbroth dilution tests: the fluoroquinolones: enrofloxacin (batch SZBA336XV), difloxacin (SZBD178XV) and norfloxacin (batch SZBD099XV); the aminoglycoside: spectinomycin (batch SZBB166XV); the lincosamide: lincomycin (batch SZBC340XV); the tetracyclines: doxycycline (batch SZBD007XV) and oxytetracycline (batch SZBC320XV); the macrolides: tilmicosin (batch SZBC345XV) and tylosin (batch SZBB160XV); the pleuromutilins: tiamulin (batch SZBC026XV) and valnemulin (batch SZBE127XV); and the phenicol: florfenicol (batch SZBC223XV); all products originated from VETRANAL, Sigma-Aldrich, Germany. The macrolide tylvalosin (Aivlosin, ECO Animal Health Ltd., UK; LOT M102A) was also included in the examinations. Lincomycin and spectinomycin were applied also in combination at a ratio of 1:2. The antibiotics were diluted and stored according to the recommendations of Hannan \[[@CR9]\]. Stock solutions of 1 mg/ml fluoroquinolones were prepared in 0.1 M NaOH; stock solution of 1 mg/ml florfenicol was prepared in 96 % ethanol and in sterile distilled water; and the rest of the stock solutions of 1 mg/ml were prepared in sterile distilled water. Dilutions of the antibiotics were freshly prepared for each microtest from the aliquots stored at −70 °C. Twofold dilutions were prepared in the range 0.039--10 μg/ml for fluoroquinolones, doxycycline and pleuromutilins, 0.25--64 μg/ml for spectinomycin, lincomycin, lincomycin-spectinomycin (1:2) combination, oxytetracycline and macrolides and 0.125--32 μg/ml for florfenicol.

The microbroth dilution examinations on 10^4^--10^5^ CCU/ml of the strains were performed according to Hannan \[[@CR9]\]. *Mycoplasma* broth medium was used in the tests as well, and each 96-well microtiter plates contained growth controls (broth medium without antibiotic), sterility controls (broth medium without antibiotic and *Mycoplasma* inoculum) and pH controls (broth medium adjusted to pH 6.8). One clinical isolate (strain MYCAV 65) was selected to be used as quality control of minimal inhibitory concentration (MIC) determination throughout the experiments. The duplicates of three clinical isolates and the duplicate of the selected strain (MYCAV 65) were tested on each 96-well microtiter plates.

The MIC values were determined from the lowest concentration of the antibiotics where no pH and colour change of the broth was detected after one week of incubation, meaning that the growth of the bacteria was completely inhibited in the broth. MIC~50~ and MIC~90~ values were defined as the lowest concentrations that inhibited the growth of 50 % or 90 % of the strains \[[@CR9]\].

Results {#Sec3}
=======

The quality control strain (MYCAV 65) showed consistent results throughout the study. Strains with elevated MIC values were found in the cases of all tested antibiotics (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 2Summary of MIC range, MIC~50~ and MIC~90~ values of the isolated *Mycoplasma* sp. 1220 strainsAntibiotic classAntibiotic agentRangeMIC~50~MIC~90~FluoroquinolonesEnrofloxacin1.25 to \>105\>10Norfloxacin10 to \>10\>10\>10Difloxacin1.25 to \>1010\>10AminoglycosideSpectinomycin4 to \>64832LincosamideLincomycin2 to \>6448Lincomycin-spectinomycin (1:2) combination2 to 3244TetracyclinesOxytetracycline2 to \>6464\>64Doxycycline0.078 to \>105\>10MacrolidesTylosin≤0.25 to \>648\>64Tilmicosin≤0.25 to \>64\>64\>64Tylvalosin≤0.25 to 160.54PleuromutilinsTiamulin0.156 to 50.6251.25Valnemulin≤0.039 to 0.312≤0.0390.078PhenicolFlorfenicol2 to 3288

Among the fluoroquinolones, the MIC values of enrofloxacin and difloxacin showed a wide range (1.25 to \>10 μg/ml), while all strains had very high MIC values for norfloxacin (≥10 μg/ml) (Fig. [2a](#Fig2){ref-type="fig"}, [b](#Fig2){ref-type="fig"} and [c](#Fig2){ref-type="fig"}). The MIC~50~ was 8 μg/ml for spectinomycin and most of the strains yielded the MIC~50~ or higher MIC values (Fig. [2d](#Fig2){ref-type="fig"}). The MICs for lincomycin clustered around the MIC~50~ value (4 μg/ml) as well, but high MIC values (\>64 μg/ml) were yielded in the case of three isolates (Fig. [2e](#Fig2){ref-type="fig"}). The MIC~50~ and the MIC~90~ values (4 μg/ml) for lincomycin-spectinomycin (1:2) combination was the same as the MIC~50~ value for lincomycin. In the case of lincomycin-spectinomycin (1:2) combination the highest concentration needed for inhibition was 32 μg/ml (Fig. [2f](#Fig2){ref-type="fig"}). Broad ranges of the MIC values were observed for tetracyclines (2 to \>64 μg/ml for oxytetracycline and 0.078 to \>10 μg/ml for doxycycline) with high MIC~50~ and MIC~90~ values (Fig. [2g](#Fig2){ref-type="fig"} and [h](#Fig2){ref-type="fig"}). The broadest ranges of MIC values were detected for tylosin and tilmicosin (≤0.25 to \>64 μg/ml) with high MIC~50~ and MIC~90~ values in the case of tilmicosin (Fig. [2i](#Fig2){ref-type="fig"} and [j](#Fig2){ref-type="fig"}). While the MIC values for tylosin showed diverse distribution, the strains' susceptibility profiles formed three groups in the case of tilmicosin (≤0.25, 4 and \>64 μg/ml) (Fig. [2j](#Fig2){ref-type="fig"}). Among the examined three macrolides (tylosin, tilmicosin and tylvalosin), tylvalosin showed the lowest MIC~50~ value (0.5 μg/ml) against the strains (Fig. [2k](#Fig2){ref-type="fig"}). From the pleuromutilins the MIC values of tiamulin were higher than those of valnemulin, and the latter compound was found to be the most active antibiotic in the examinations (Fig. [2l](#Fig2){ref-type="fig"} and [m](#Fig2){ref-type="fig"}). In the case of florfenicol, the susceptibility profiles of most strains were similar to each other and showed the MIC~50~ and MIC~90~ value (8 μg/ml) or its two-fold lower dilution (4 μg/ml) with few exceptions (Fig. [2n](#Fig2){ref-type="fig"}).Fig. 2MIC distribution of test antibiotics against *Mycoplasma* sp. 1220 isolates

*M*. sp. 1220 strains isolated year by year from the same farms and from the same tissue types (e.g. strains MYCAV 34, 53 and 67 from Szentes, strains MYCAV 50, 70, 176 and 177 from Cered, or strains MYCAV 38 and 202 from Kelebia) showed elevated MIC values from year to year in the cases of certain antibiotics. Higher MIC values were detected in subsequent isolates for lincomycin, lincomycin-spectinomycin combination, tetracyclines (both oxytetracycline and doxycycline), macrolides (tylosin, tilmicosin and tylvalosin), tiamulin and for florfenicol as well.

Discussion {#Sec4}
==========

Information about the susceptibility of *M*. sp. 1220 strains to antimicrobials is scarce, as until to date the sole published reference concerning the antibiotic susceptibility profile of this species is a review of Stipkovits and Szathmary \[[@CR3]\]. Stipkovits and Szathmary determined the values of enrofloxacin, tylosin, chlortetracycline, oxytetracycline, doxycycline, tiamulin and lincomycin in *Mycoplasma* species affecting waterfowl (*M. anatis*, *M. cloacale*, *M. anseris* and *M*. sp. 1220), although detailed data of their method is lacking \[[@CR3]\]. Thus we are facing the absence of reports about the antibiotic susceptibility of *M*. sp. 1220 and also of other *Mycoplasma* species occurring in waterfowl. Therefore, the results of the current study are also compared to data of antibiotic susceptibility of the well-studied *Mycoplasma* species of poultry: *M. synoviae* and *M. gallisepticum*.

Elevated MIC values were reported previously in the case of the fluoroquinolones, especially of enrofloxacin in *M*. sp. 1220 (MIC~50~ 2 μg/ml and MIC~90~ 4 μg/ml) and other *Mycoplasma* species of poultry \[[@CR3], [@CR13], [@CR20], [@CR21]\]. In addition, the increasing occurrence of quinolone-resistant *M. synoviae* and *M. gallisepticum* field isolates were also observed \[[@CR13], [@CR22]\]. In the current study, the detected MIC~50~ values (5 μg/ml for enrofloxacin, 10 μg/ml for difloxacin and ≥10 μg/ml for norfloxacin) were even higher than the ones reported before \[[@CR3], [@CR13], [@CR20]--[@CR22]\], confirming the observation of increasing quinolone-resistance in *Mycoplasma* species. In order to save these antibiotics for human disease treatment the directive was to reduce the use of these agents in livestock. Former efforts for the prevention of the appearance of quinolone-resistant species are proved to be unsuccessful considering the observed dramatic elevations in the MIC values of these antibiotics in avian *Mycoplasma* species \[[@CR13], [@CR21], [@CR23]\].

Administration of the combination of lincomycin and spectinomycin could reduce the egg infertility rates and increase the hatching rates and the egg production in *M*. sp. 1220 infected geese \[[@CR11]\]. The lincomycin-spectinomycin therapy was proved to be effective against other *Mycoplasma* species as well; however, application of spectinomycin in monotherapy is not recommended for its insufficient effectiveness and relatively high MIC values in in vitro experiments \[[@CR12]\]. In vitro effectiveness of lincomycin at 2 μg/ml MIC~50~ values against *M*. sp. 1220, *M. anseris* and *M. anatis* species has been reported \[[@CR3]\]. In the present study, all isolates showed elevated MIC values for spectinomycin, lincomycin and lincomycin-spectinomycin combination. The growth of a couple of strains was not inhibited even at the highest concentrations used (64 μg/ml) for spectinomycin and lincomycin individually. The combination of the two antibiotics improved their effectiveness, as lincomycin-spectinomycin combination could inhibit the growth of all examined strains within the concentration range used (0.25 to 64 μg/ml) and lower MIC~90~ value was observed also.

Previously, tetracyclines (chlortetracycline, doxycycline and oxytetracycline) showed 1--2 μg/ml MIC values against *M*. sp. 1220 strains. Growth of other *Mycoplasma* species isolated from waterfowl were inhibited at 2--4 μg/ml MIC~50~ values using the same antibiotics \[[@CR3]\]. Previously *Mycoplasma* species infecting poultry were observed to be inhibited by elevated MIC values, although with exceptions, as *M. synoviae* strains showed high susceptibility to doxycycline in the Netherlands \[[@CR12]--[@CR14]\]. In the current study, although the *M*. sp. 1220 strains showed broad ranges of MIC values for oxytetracycline and doxycycline, more than 50 % of the strains were inhibited by only higher antibiotic concentrations (64 and 5 μg/ml, respectively) and MIC~90~ values exceeded the concentration ranges used for both compounds. These results show a dramatic increase of the MIC values of tetracyclines against *M*. sp. 1220 strains and reveals the presence of probably highly resistant strains in Hungary.

Macrolides, especially tylvalosin have good in vitro effectiveness against most *Mycoplasma* species infecting poultry, showing lower MIC values in previous examinations than quinolones and tetracyclines \[[@CR3], [@CR12]--[@CR15]\]. However, *M. gallisepticum* could develop resistance rapidly to these compounds, especially to tilmicosin \[[@CR24]\]. Earlier, the MIC~50~ values in *M.* sp. 1220, *M. anatis, M. anseris* and *M. cloacale* strains were defined to be 2 μg/ml for tylosin \[[@CR3]\]. In the current study, the MIC~50~ value (8 μg/ml) of tylosin was higher than the previous observation \[[@CR3]\], and the MIC~90~ value exceeded the concentration range used in the experiment. However, high variability was observed in the susceptibility of the strains to this compound. Similarly, wide range of the MIC values was detected for tilmicosin, highlighting the necessity of susceptibility testing before antibiotic treatments. As opposed to the diverse susceptibility profiles of the strains for tylosin, the MIC values of tilmicosin were categorized into three separate groups. The observed distribution of the MIC values is likely in association with the capability of *Mycoplasma* sp. 1220 to develop resistance more rapidly to tilmicosin (i.e. with one or two mutations) than to other macrolides. The same phenomenon was described in other *Mycoplasma* species as well \[[@CR24]\]. Out of the three macrolides examined in the study, tylvalosin proved to be the most effective agent against *M*. sp. 1220 strains, showing lower MIC~50~ value (0.5 μg/ml) against the pathogen than the majority of the antibiotics tested.

Pleuromutilins showed good in vitro effectiveness against avian *Mycoplasma* species in previous studies and low tendency of the development of resistance to these agents has been reported \[[@CR16]--[@CR18], [@CR21]\]. Tiamulin was used successfully for the treatment of mycoplasmosis and its effectiveness was similar to spectinomycin therapy in the treated geese \[[@CR11]\]. Stipkovits and Szathmary described low MIC values (MIC~50~: 0.06 μg/ml, MIC~90~: 0.25 μg/ml) of tiamulin in the case of *M.* sp. 1220, and similarly low MIC~50~ values (0.125--1 μg/ml) were observed against *M. anseris*, *M. anatis* and *M. cloacale* \[[@CR3]\]. In the present study, pleuromutilins were found to be the most effective antibiotic agents and the examined compounds, especially valnemulin showed high in vitro effectiveness against all tested isolates of the pathogen. However, it is noteworthy, that strains with elevated MIC values were detected for tiamulin (MIC: 2.5--5 μg/ml) and even for valnemulin (MIC: 0.312 μg/ml). Although the low MIC values of valnemulin against *M*. sp. 1220 strains in vitro are promising for its clinical use, it should be noted that in a previous study only a single mutation in *M. gallisepticum* could cause elevation in the MIC values of valnemulin \[[@CR17]\]. To date, the use of pleuromutilins in humans is limited, as only one commercially available product is authorized containing this active substance. However, bacterial strains resistant to pleuromutilins have already been described and these strains also show multidrug resistance, which warrants the prudent use of these antibiotic agents \[[@CR25]\].

Phenicols showed good in vitro activity against *Mycoplasma* species of poultry, but information about their effectiveness in waterfowl is lacking \[[@CR26], [@CR27]\]. In the present study, most of the *M*. sp. 1220 isolates yielded the same MIC values (4 or 8 μg/ml) for florfenicol, and only two isolates (originating from the same region) showed elevated MIC values compared to the MIC~50~ (8 μg/ml), one of them reaching the highest antibiotic concentration (32 μg/ml) used.

The elevated MIC values of several antibiotics detected in subsequent isolates from the same farms from year to year are likely in association with the inconsistent use of antibiotics, the rapid development of antibiotic resistance and highlight the importance of susceptibility testing before therapy and responsible use of antimicrobial drugs.

Conclusion {#Sec5}
==========

In the present examinations the antibiotic susceptibility profiles of thirty-eight *M*. sp. 1220 strains isolated in Hungary were determined. To the best of our knowledge, this is the first detailed study about the antibiotic susceptibility of *M*. sp. 1220, a pathogen which could cause significant economic losses in waterfowl flocks. Valnemulin, tiamulin and tylvalosin were found to be the most effective antibiotics in the present study. Most of the isolates showed elevated MIC values for more than one agent, but none of the strains yielded high MIC values for all the examined antibiotics. Nevertheless, our results confirmed that increasing resistance could be observed in the cases of several antibiotics. These findings highlight the consistent use of antibiotics and the need for determination of antibiotic susceptibility of *Mycoplasma* species before treatment.

MIC

:   Minimal inhibitory concentrations
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